APO Research
Talk to an analyst

APO RESEARCH · REPORT

Orally Administered Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Orally Administered Vaccine Market Analysis and Forecast 2026-2032

21 December 2025193 pages

Choose your research edition.

Industry ResearchOrally Administered Vaccine Industry Research Report 2026135 pages · $2,950 USDIndustry Growth & TrendsGlobal Orally Administered Vaccine Industry Growth and Trends Forecast to 2032111 pages · $3,450 USDMarket StructureGlobal Orally Administered Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Orally Administered Vaccine Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Orally Administered Vaccine Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Orally Administered Vaccine market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Orally Administered Vaccine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Orally Administered Vaccine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Orally Administered Vaccine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Orally Administered Vaccine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Orally Administered Vaccine include Lanzhou Institute, Sanofi, Merck, GSK, Tiantan Biological, Valneva, Vabiotech, Shanghai United Cell and Serum Institute, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Orally Administered Vaccine, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Orally Administered Vaccine, also provides the sales of main regions and countries. Of the upcoming market potential for Orally Administered Vaccine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Orally Administered Vaccine sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Orally Administered Vaccine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Orally Administered Vaccine sales, projected growth trends, production technology, application and end-user industry.

Orally Administered Vaccine Segment by Company

Lanzhou Institute

Sanofi

Merck

GSK

Tiantan Biological

Valneva

Vabiotech

Shanghai United Cell

Serum Institute

PaxVax

Panacea Biotec Ltd

Halfkin Bio-Pharmaceuticals

EuBiologics

Bio-Med

Bibcol

Orally Administered Vaccine Segment by Type

Rotavirus Vaccine

Oral Polio Vaccine

Cholera Vaccine

Other

Orally Administered Vaccine Segment by Application

Public

Private

Orally Administered Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Orally Administered Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Orally Administered Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Orally Administered Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Orally Administered Vaccine in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Orally Administered Vaccine manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Orally Administered Vaccine sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Orally Administered Vaccine Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Rotavirus Vaccine Major Manufacturers Table 3. Oral Polio Vaccine Major Manufacturers Table 4. Cholera Vaccine Major Manufacturers Table 5. Other Major Manufacturers Table 6. Global Orally Administered Vaccine Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Public Major Manufacturers Table 8. Private Major Manufacturers Table 9. Orally Administered Vaccine Industry Trends Table 10. Orally Administered Vaccine Industry Drivers Table 11. Orally Administered Vaccine Industry Opportunities and Challenges Table 12. Orally Administered Vaccine Industry Restraints Table 13. Global Orally Administered Vaccine Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 14. Global Orally Administered Vaccine Revenue by Region (2021-2026) & (US$ Million) Table 15. Global Orally Administered Vaccine Revenue by Region (2027-2032) & (US$ Million) Table 16. Global Orally Administered Vaccine Revenue Market Share by Region (2021-2026) Table 17. Global Orally Administered Vaccine Revenue Market Share by Region (2027-2032) Table 18. Global Orally Administered Vaccine Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (k units) Table 19. Global Orally Administered Vaccine Sales by Region (2021-2026) & (k units) Table 20. Global Orally Administered Vaccine Sales by Region (2027-2032) & (k units) Table 21. Global Orally Administered Vaccine Sales Market Share by Region (2021-2026) Table 22. Global Orally Administered Vaccine Sales Market Share by Region (2027-2032) Table 23. Global Orally Administered Vaccine Revenue by Manufacturers (US$ Million) & (2021-2026) Table 24. Global Orally Administered Vaccine Revenue Market Share by Manufacturers (2021-2026) Table 25. Global Orally Administered Vaccine Sales by Manufacturers (US$ Million) & (2021-2026) Table 26. Global Orally Administered Vaccine Sales Market Share by Manufacturers (2021-2026) Table 27. Global Orally Administered Vaccine Sales Price (US$/unit) of Manufacturers (2021-2026) Table 28. Global Orally Administered Vaccine Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 29. Global Orally Administered Vaccine Key Manufacturers Manufacturing Sites & Headquarters Table 30. Global Orally Administered Vaccine Manufacturers, Product Type & Application Table 31. Global Orally Administered Vaccine Manufacturers' Establishment Date Table 32. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 33. Global Orally Administered Vaccine by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 34. Global Orally Administered Vaccine Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Orally Administered Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 36. Global Orally Administered Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 37. Global Orally Administered Vaccine Revenue Market Share by Type (2021-2026) Table 38. Global Orally Administered Vaccine Revenue Market Share by Type (2027-2032) Table 39. Global Orally Administered Vaccine Sales by Type 2021 VS 2025 VS 2032 (k units) Table 40. Global Orally Administered Vaccine Sales by Type (2021-2026) & (k units) Table 41. Global Orally Administered Vaccine Sales by Type (2027-2032) & (k units) Table 42. Global Orally Administered Vaccine Sales Market Share by Type (2021-2026) Table 43. Global Orally Administered Vaccine Sales Market Share by Type (2027-2032) Table 44. Global Orally Administered Vaccine Price by Type (2021-2026) & (US$/unit) Table 45. Global Orally Administered Vaccine Price by Type (2027-2032) & (US$/unit) Table 46. Global Orally Administered Vaccine Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Orally Administered Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 48. Global Orally Administered Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 49. Global Orally Administered Vaccine Revenue Market Share by Application (2021-2026) Table 50. Global Orally Administered Vaccine Revenue Market Share by Application (2027-2032) Table 51. Global Orally Administered Vaccine Sales by Application 2021 VS 2025 VS 2032 (k units) Table 52. Global Orally Administered Vaccine Sales by Application (2021-2026) & (k units) Table 53. Global Orally Administered Vaccine Sales by Application (2027-2032) & (k units) Table 54. Global Orally Administered Vaccine Sales Market Share by Application (2021-2026) Table 55. Global Orally Administered Vaccine Sales Market Share by Application (2027-2032) Table 56. Global Orally Administered Vaccine Price by Application (2021-2026) & (US$/unit) Table 57. Global Orally Administered Vaccine Price by Application (2027-2032) & (US$/unit) Table 58. Lanzhou Institute Company Information Table 59. Lanzhou Institute Business Overview Table 60. Lanzhou Institute Orally Administered Vaccine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 61. Lanzhou Institute Orally Administered Vaccine Product Portfolio Table 62. Lanzhou Institute Recent Development Table 63. Sanofi Company Information Table 64. Sanofi Business Overview Table 65. Sanofi Orally Administered Vaccine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 66. Sanofi Orally Administered Vaccine Product Portfolio Table 67. Sanofi Recent Development Table 68. Merck Company Information Table 69. Merck Business Overview Table 70. Merck Orally Administered Vaccine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 71. Merck Orally Administered Vaccine Product Portfolio Table 72. Merck Recent Development Table 73. GSK Company Information Table 74. GSK Business Overview Table 75. GSK Orally Administered Vaccine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 76. GSK Orally Administered Vaccine Product Portfolio Table 77. GSK Recent Development Table 78. Tiantan Biological Company Information Table 79. Tiantan Biological Business Overview Table 80. Tiantan Biological Orally Administered Vaccine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 81. Tiantan Biological Orally Administered Vaccine Product Portfolio Table 82. Tiantan Biological Recent Development Table 83. Valneva Company Information Table 84. Valneva Business Overview Table 85. Valneva Orally Administered Vaccine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 86. Valneva Orally Administered Vaccine Product Portfolio Table 87. Valneva Recent Development Table 88. Vabiotech Company Information Table 89. Vabiotech Business Overview Table 90. Vabiotech Orally Administered Vaccine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 91. Vabiotech Orally Administered Vaccine Product Portfolio Table 92. Vabiotech Recent Development Table 93. Shanghai United Cell Company Information Table 94. Shanghai United Cell Business Overview Table 95. Shanghai United Cell Orally Administered Vaccine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 96. Shanghai United Cell Orally Administered Vaccine Product Portfolio Table 97. Shanghai United Cell Recent Development Table 98. Serum Institute Company Information Table 99. Serum Institute Business Overview Table 100. Serum Institute Orally Administered Vaccine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 101. Serum Institute Orally Administered Vaccine Product Portfolio Table 102. Serum Institute Recent Development Table 103. PaxVax Company Information Table 104. PaxVax Business Overview Table 105. PaxVax Orally Administered Vaccine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 106. PaxVax Orally Administered Vaccine Product Portfolio Table 107. PaxVax Recent Development Table 108. Panacea Biotec Ltd Company Information Table 109. Panacea Biotec Ltd Business Overview Table 110. Panacea Biotec Ltd Orally Administered Vaccine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 111. Panacea Biotec Ltd Orally Administered Vaccine Product Portfolio Table 112. Panacea Biotec Ltd Recent Development Table 113. Halfkin Bio-Pharmaceuticals Company Information Table 114. Halfkin Bio-Pharmaceuticals Business Overview Table 115. Halfkin Bio-Pharmaceuticals Orally Administered Vaccine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 116. Halfkin Bio-Pharmaceuticals Orally Administered Vaccine Product Portfolio Table 117. Halfkin Bio-Pharmaceuticals Recent Development Table 118. EuBiologics Company Information Table 119. EuBiologics Business Overview Table 120. EuBiologics Orally Administered Vaccine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 121. EuBiologics Orally Administered Vaccine Product Portfolio Table 122. EuBiologics Recent Development Table 123. Bio-Med Company Information Table 124. Bio-Med Business Overview Table 125. Bio-Med Orally Administered Vaccine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 126. Bio-Med Orally Administered Vaccine Product Portfolio Table 127. Bio-Med Recent Development Table 128. Bibcol Company Information Table 129. Bibcol Business Overview Table 130. Bibcol Orally Administered Vaccine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 131. Bibcol Orally Administered Vaccine Product Portfolio Table 132. Bibcol Recent Development Table 133. North America Orally Administered Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 134. North America Orally Administered Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 135. North America Orally Administered Vaccine Sales by Type (2021-2026) & (k units) Table 136. North America Orally Administered Vaccine Sales by Type (2027-2032) & (k units) Table 137. North America Orally Administered Vaccine Sales Price by Type (2021-2026) & (US$/unit) Table 138. North America Orally Administered Vaccine Sales Price by Type (2027-2032) & (US$/unit) Table 139. North America Orally Administered Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 140. North America Orally Administered Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 141. North America Orally Administered Vaccine Sales by Application (2021-2026) & (k units) Table 142. North America Orally Administered Vaccine Sales by Application (2027-2032) & (k units) Table 143. North America Orally Administered Vaccine Sales Price by Application (2021-2026) & (US$/unit) Table 144. North America Orally Administered Vaccine Sales Price by Application (2027-2032) & (US$/unit) Table 145. North America Orally Administered Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 146. North America Orally Administered Vaccine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 147. North America Orally Administered Vaccine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 148. North America Orally Administered Vaccine Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 149. North America Orally Administered Vaccine Sales by Country (2021-2026) & (k units) Table 150. North America Orally Administered Vaccine Sales by Country (2027-2032) & (k units) Table 151. North America Orally Administered Vaccine Sales Price by Country (2021-2026) & (US$/unit) Table 152. North America Orally Administered Vaccine Sales Price by Country (2027-2032) & (US$/unit) Table 153. United States Orally Administered Vaccine Revenue (2021-2032) & (US$ Million) Table 154. Canada Orally Administered Vaccine Revenue (2021-2032) & (US$ Million) Table 155. Mexico Orally Administered Vaccine Revenue (2021-2032) & (US$ Million) Table 156. Europe Orally Administered Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 157. Europe Orally Administered Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 158. Europe Orally Administered Vaccine Sales by Type (2021-2026) & (k units) Table 159. Europe Orally Administered Vaccine Sales by Type (2027-2032) & (k units) Table 160. Europe Orally Administered Vaccine Sales Price by Type (2021-2026) & (US$/unit) Table 161. Europe Orally Administered Vaccine Sales Price by Type (2027-2032) & (US$/unit) Table 162. Europe Orally Administered Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 163. Europe Orally Administered Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 164. Europe Orally Administered Vaccine Sales by Application (2021-2026) & (k units) Table 165. Europe Orally Administered Vaccine Sales by Application (2027-2032) & (k units) Table 166. Europe Orally Administered Vaccine Sales Price by Application (2021-2026) & (US$/unit) Table 167. Europe Orally Administered Vaccine Sales Price by Application (2027-2032) & (US$/unit) Table 168. Europe Orally Administered Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 169. Europe Orally Administered Vaccine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 170. Europe Orally Administered Vaccine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 171. Europe Orally Administered Vaccine Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 172. Europe Orally Administered Vaccine Sales by Country (2021-2026) & (k units) Table 173. Europe Orally Administered Vaccine Sales by Country (2027-2032) & (k units) Table 174. Europe Orally Administered Vaccine Sales Price by Country (2021-2026) & (US$/unit) Table 175. Europe Orally Administered Vaccine Sales Price by Country (2027-2032) & (US$/unit) Table 176. Germany Orally Administered Vaccine Revenue (2021-2032) & (US$ Million) Table 177. France Orally Administered Vaccine Revenue (2021-2032) & (US$ Million) Table 178. U.K. Orally Administered Vaccine Revenue (2021-2032) & (US$ Million) Table 179. Italy Orally Administered Vaccine Revenue (2021-2032) & (US$ Million) Table 180. Russia Orally Administered Vaccine Revenue (2021-2032) & (US$ Million) Table 181. Spain Orally Administered Vaccine Revenue (2021-2032) & (US$ Million) Table 182. Netherlands Orally Administered Vaccine Revenue (2021-2032) & (US$ Million) Table 183. Switzerland Orally Administered Vaccine Revenue (2021-2032) & (US$ Million) Table 184. Sweden Orally Administered Vaccine Revenue (2021-2032) & (US$ Million) Table 185. Poland Orally Administered Vaccine Revenue (2021-2032) & (US$ Million) Table 186. China Orally Administered Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 187. China Orally Administered Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 188. China Orally Administered Vaccine Sales by Type (2021-2026) & (k units) Table 189. China Orally Administered Vaccine Sales by Type (2027-2032) & (k units) Table 190. China Orally Administered Vaccine Sales Price by Type (2021-2026) & (US$/unit) Table 191. China Orally Administered Vaccine Sales Price by Type (2027-2032) & (US$/unit) Table 192. China Orally Administered Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 193. China Orally Administered Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 194. China Orally Administered Vaccine Sales by Application (2021-2026) & (k units) Table 195. China Orally Administered Vaccine Sales by Application (2027-2032) & (k units) Table 196. China Orally Administered Vaccine Sales Price by Application (2021-2026) & (US$/unit) Table 197. China Orally Administered Vaccine Sales Price by Application (2027-2032) & (US$/unit) Table 198. Asia Orally Administered Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 199. Asia Orally Administered Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 200. Asia Orally Administered Vaccine Sales by Type (2021-2026) & (k units) Table 201. Asia Orally Administered Vaccine Sales by Type (2027-2032) & (k units) Table 202. Asia Orally Administered Vaccine Sales Price by Type (2021-2026) & (US$/unit) Table 203. Asia Orally Administered Vaccine Sales Price by Type (2027-2032) & (US$/unit) Table 204. Asia Orally Administered Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 205. Asia Orally Administered Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 206. Asia Orally Administered Vaccine Sales by Application (2021-2026) & (k units) Table 207. Asia Orally Administered Vaccine Sales by Application (2027-2032) & (k units) Table 208. Asia Orally Administered Vaccine Sales Price by Application (2021-2026) & (US$/unit) Table 209. Asia Orally Administered Vaccine Sales Price by Application (2027-2032) & (US$/unit) Table 210. Asia Orally Administered Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 211. Asia Orally Administered Vaccine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 212. Asia Orally Administered Vaccine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 213. Asia Orally Administered Vaccine Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 214. Asia Orally Administered Vaccine Sales by Country (2021-2026) & (k units) Table 215. Asia Orally Administered Vaccine Sales by Country (2027-2032) & (k units) Table 216. Asia Orally Administered Vaccine Sales Price by Country (2021-2026) & (US$/unit) Table 217. Asia Orally Administered Vaccine Sales Price by Country (2027-2032) & (US$/unit) Table 218. Japan Orally Administered Vaccine Revenue (2021-2032) & (US$ Million) Table 219. South Korea Orally Administered Vaccine Revenue (2021-2032) & (US$ Million) Table 220. India Orally Administered Vaccine Revenue (2021-2032) & (US$ Million) Table 221. Australia Orally Administered Vaccine Revenue (2021-2032) & (US$ Million) Table 222. Taiwan Orally Administered Vaccine Revenue (2021-2032) & (US$ Million) Table 223. Southeast Asia Orally Administered Vaccine Revenue (2021-2032) & (US$ Million) Table 224. SAMEA Orally Administered Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 225. SAMEA Orally Administered Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 226. SAMEA Orally Administered Vaccine Sales by Type (2021-2026) & (k units) Table 227. SAMEA Orally Administered Vaccine Sales by Type (2027-2032) & (k units) Table 228. SAMEA Orally Administered Vaccine Sales Price by Type (2021-2026) & (US$/unit) Table 229. SAMEA Orally Administered Vaccine Sales Price by Type (2027-2032) & (US$/unit) Table 230. SAMEA Orally Administered Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 231. SAMEA Orally Administered Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 232. SAMEA Orally Administered Vaccine Sales by Application (2021-2026) & (k units) Table 233. SAMEA Orally Administered Vaccine Sales by Application (2027-2032) & (k units) Table 234. SAMEA Orally Administered Vaccine Sales Price by Application (2021-2026) & (US$/unit) Table 235. SAMEA Orally Administered Vaccine Sales Price by Application (2027-2032) & (US$/unit) Table 236. SAMEA Orally Administered Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 237. SAMEA Orally Administered Vaccine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 238. SAMEA Orally Administered Vaccine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 239. SAMEA Orally Administered Vaccine Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 240. SAMEA Orally Administered Vaccine Sales by Country (2021-2026) & (k units) Table 241. SAMEA Orally Administered Vaccine Sales by Country (2027-2032) & (k units) Table 242. SAMEA Orally Administered Vaccine Sales Price by Country (2021-2026) & (US$/unit) Table 243. SAMEA Orally Administered Vaccine Sales Price by Country (2027-2032) & (US$/unit) Table 244. Brazil Orally Administered Vaccine Revenue (2021-2032) & (US$ Million) Table 245. Argentina Orally Administered Vaccine Revenue (2021-2032) & (US$ Million) Table 246. Chile Orally Administered Vaccine Revenue (2021-2032) & (US$ Million) Table 247. Colombia Orally Administered Vaccine Revenue (2021-2032) & (US$ Million) Table 248. Peru Orally Administered Vaccine Revenue (2021-2032) & (US$ Million) Table 249. Saudi Arabia Orally Administered Vaccine Revenue (2021-2032) & (US$ Million) Table 250. Israel Orally Administered Vaccine Revenue (2021-2032) & (US$ Million) Table 251. UAE Orally Administered Vaccine Revenue (2021-2032) & (US$ Million) Table 252. Turkey Orally Administered Vaccine Revenue (2021-2032) & (US$ Million) Table 253. Iran Orally Administered Vaccine Revenue (2021-2032) & (US$ Million) Table 254. Egypt Orally Administered Vaccine Revenue (2021-2032) & (US$ Million) Table 255. Key Raw Materials Table 256. Raw Materials Key Suppliers Table 257. Orally Administered Vaccine Distributors List Table 258. Orally Administered Vaccine Customers List Table 259. Research Programs/Design for This Report Table 260. Authors List of This Report Table 261. Secondary Sources Table 262. Primary Sources List of Figures Figure 1. Orally Administered Vaccine Image Figure 2. Global Orally Administered Vaccine Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Orally Administered Vaccine Market Size Share 2021 VS 2025 VS 2032 Figure 4. Rotavirus Vaccine Image Figure 5. Oral Polio Vaccine Image Figure 6. Cholera Vaccine Image Figure 7. Other Image Figure 8. Global Orally Administered Vaccine Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Orally Administered Vaccine Market Size Share 2021 VS 2025 VS 2032 Figure 10. Public Image Figure 11. Private Image Figure 12. Global Orally Administered Vaccine Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Orally Administered Vaccine Revenue (2021-2032) & (US$ Million) Figure 14. Global Orally Administered Vaccine Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 15. Global Orally Administered Vaccine Revenue Market Share by Region: 2025 Versus 2032 Figure 16. Global Orally Administered Vaccine Revenue Market Share by Region (2021-2032) Figure 17. Global Orally Administered Vaccine Sales (2021-2032) & (k units) Figure 18. Global Orally Administered Vaccine Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 19. Global Orally Administered Vaccine Sales Market Share by Region (2021-2032) Figure 20. US & Canada & Mexico Orally Administered Vaccine Sales YoY (2021-2032) & (k units) Figure 21. Europe Orally Administered Vaccine Sales YoY (2021-2032) & (k units) Figure 22. China Orally Administered Vaccine Sales YoY (2021-2032) & (k units) Figure 23. Asia (Excluding China) Orally Administered Vaccine Sales YoY (2021-2032) & (k units) Figure 24. South America, Middle East and Africa Orally Administered Vaccine Sales YoY (2021-2032) & (k units) Figure 25. Global Orally Administered Vaccine Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 26. Global Orally Administered Vaccine Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 27. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 28. Global Orally Administered Vaccine Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 29. Global Orally Administered Vaccine Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 30. Global Orally Administered Vaccine Revenue Market Share by Type (2021-2032) Figure 31. Global Orally Administered Vaccine Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 32. Global Orally Administered Vaccine Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 33. Global Orally Administered Vaccine Sales Market Share by Type (2021-2032) Figure 34. Global Orally Administered Vaccine Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 35. Global Orally Administered Vaccine Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 36. Global Orally Administered Vaccine Revenue Market Share by Application (2021-2032) Figure 37. Global Orally Administered Vaccine Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 38. Global Orally Administered Vaccine Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 39. Global Orally Administered Vaccine Sales Market Share by Application (2021-2032) Figure 40. North America Orally Administered Vaccine Revenue Share by Type (2021-2032) Figure 41. North America Orally Administered Vaccine Sales Share by Type (2021-2032) Figure 42. North America Orally Administered Vaccine Revenue Share by Application (2021-2032) Figure 43. North America Orally Administered Vaccine Sales Share by Application (2021-2032) Figure 44. North America Orally Administered Vaccine Revenue Share by Country (2021-2032) Figure 45. North America Orally Administered Vaccine Sales Share by Country (2021-2032) Figure 46. Europe Orally Administered Vaccine Revenue Share by Type (2021-2032) Figure 47. Europe Orally Administered Vaccine Sales Share by Type (2021-2032) Figure 48. Europe Orally Administered Vaccine Revenue Share by Application (2021-2032) Figure 49. Europe Orally Administered Vaccine Sales Share by Application (2021-2032) Figure 50. Europe Orally Administered Vaccine Revenue Share by Country (2021-2032) Figure 51. Europe Orally Administered Vaccine Sales Share by Country (2021-2032) Figure 52. China Orally Administered Vaccine Revenue Share by Type (2021-2032) Figure 53. China Orally Administered Vaccine Sales Share by Type (2021-2032) Figure 54. China Orally Administered Vaccine Revenue Share by Application (2021-2032) Figure 55. China Orally Administered Vaccine Sales Share by Application (2021-2032) Figure 56. Asia Orally Administered Vaccine Revenue Share by Type (2021-2032) Figure 57. Asia Orally Administered Vaccine Sales Share by Type (2021-2032) Figure 58. Asia Orally Administered Vaccine Revenue Share by Application (2021-2032) Figure 59. Asia Orally Administered Vaccine Sales Share by Application (2021-2032) Figure 60. Asia Orally Administered Vaccine Revenue Share by Country (2021-2032) Figure 61. Asia Orally Administered Vaccine Sales Share by Country (2021-2032) Figure 62. SAMEA Orally Administered Vaccine Revenue Share by Type (2021-2032) Figure 63. SAMEA Orally Administered Vaccine Sales Share by Type (2021-2032) Figure 64. SAMEA Orally Administered Vaccine Revenue Share by Application (2021-2032) Figure 65. SAMEA Orally Administered Vaccine Sales Share by Application (2021-2032) Figure 66. SAMEA Orally Administered Vaccine Revenue Share by Country (2021-2032) Figure 67. SAMEA Orally Administered Vaccine Sales Share by Country (2021-2032) Figure 68. Orally Administered Vaccine Value Chain Figure 69. Manufacturing Cost Structure Figure 70. Orally Administered Vaccine Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Rotavirus Vaccine
  • Oral Polio Vaccine
  • Cholera Vaccine
  • Other
Applications
  • Public
  • Private
Companies covered
  • Lanzhou Institute
  • Sanofi
  • Merck
  • GSK
  • Tiantan Biological
  • Valneva
  • Vabiotech
  • Shanghai United Cell
  • Serum Institute
  • PaxVax
  • Panacea Biotec Ltd
  • Halfkin Bio-Pharmaceuticals
  • EuBiologics
  • Bio-Med
  • Bibcol

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Orally Administered Vaccine Market by Type
  3. 1.2.1 Global Orally Administered Vaccine Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Rotavirus Vaccine
  5. 1.2.3 Oral Polio Vaccine
  6. 1.2.4 Cholera Vaccine
  7. 1.2.5 Other
  8. 1.3 Orally Administered Vaccine Market by Application
  9. 1.3.1 Global Orally Administered Vaccine Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Public
  11. 1.3.3 Private
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Orally Administered Vaccine Market Dynamics
  1. 2.1 Orally Administered Vaccine Industry Trends
  2. 2.2 Orally Administered Vaccine Industry Drivers
  3. 2.3 Orally Administered Vaccine Industry Opportunities and Challenges
  4. 2.4 Orally Administered Vaccine Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Orally Administered Vaccine Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Orally Administered Vaccine Revenue by Region
  3. 3.2.1 Global Orally Administered Vaccine Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Orally Administered Vaccine Revenue by Region (2021-2026)
  5. 3.2.3 Global Orally Administered Vaccine Revenue by Region (2027-2032)
  6. 3.2.4 Global Orally Administered Vaccine Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Orally Administered Vaccine Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Orally Administered Vaccine Sales by Region
  9. 3.4.1 Global Orally Administered Vaccine Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Orally Administered Vaccine Sales by Region (2021-2026)
  11. 3.4.3 Global Orally Administered Vaccine Sales by Region (2027-2032)
  12. 3.4.4 Global Orally Administered Vaccine Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Orally Administered Vaccine Revenue by Manufacturers
  2. 4.1.1 Global Orally Administered Vaccine Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Orally Administered Vaccine Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Orally Administered Vaccine Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Orally Administered Vaccine Sales by Manufacturers
  6. 4.2.1 Global Orally Administered Vaccine Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Orally Administered Vaccine Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Orally Administered Vaccine Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Orally Administered Vaccine Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Orally Administered Vaccine Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Orally Administered Vaccine Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Orally Administered Vaccine Manufacturers, Product Type & Application
  13. 4.7 Global Orally Administered Vaccine Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Orally Administered Vaccine Market CR5 and HHI
  16. 4.8.2 2025 Orally Administered Vaccine Tier 1, Tier 2, and Tier 3
5 Orally Administered Vaccine Market by Type
  1. 5.1 Global Orally Administered Vaccine Revenue by Type
  2. 5.1.1 Global Orally Administered Vaccine Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Orally Administered Vaccine Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Orally Administered Vaccine Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Orally Administered Vaccine Sales by Type
  6. 5.2.1 Global Orally Administered Vaccine Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Orally Administered Vaccine Sales by Type (2021-2032) & (k units)
  8. 5.2.3 Global Orally Administered Vaccine Sales Market Share by Type (2021-2032)
  9. 5.3 Global Orally Administered Vaccine Price by Type
6 Orally Administered Vaccine Market by Application
  1. 6.1 Global Orally Administered Vaccine Revenue by Application
  2. 6.1.1 Global Orally Administered Vaccine Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Orally Administered Vaccine Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Orally Administered Vaccine Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Orally Administered Vaccine Sales by Application
  6. 6.2.1 Global Orally Administered Vaccine Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Orally Administered Vaccine Sales by Application (2021-2032) & (k units)
  8. 6.2.3 Global Orally Administered Vaccine Sales Market Share by Application (2021-2032)
  9. 6.3 Global Orally Administered Vaccine Price by Application
7 Company Profiles
  1. 7.1 Lanzhou Institute
  2. 7.1.1 Lanzhou Institute Company Information
  3. 7.1.2 Lanzhou Institute Business Overview
  4. 7.1.3 Lanzhou Institute Orally Administered Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Lanzhou Institute Orally Administered Vaccine Product Portfolio
  6. 7.1.5 Lanzhou Institute Recent Developments
  7. 7.2 Sanofi
  8. 7.2.1 Sanofi Company Information
  9. 7.2.2 Sanofi Business Overview
  10. 7.2.3 Sanofi Orally Administered Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Sanofi Orally Administered Vaccine Product Portfolio
  12. 7.2.5 Sanofi Recent Developments
  13. 7.3 Merck
  14. 7.3.1 Merck Company Information
  15. 7.3.2 Merck Business Overview
  16. 7.3.3 Merck Orally Administered Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Merck Orally Administered Vaccine Product Portfolio
  18. 7.3.5 Merck Recent Developments
  19. 7.4 GSK
  20. 7.4.1 GSK Company Information
  21. 7.4.2 GSK Business Overview
  22. 7.4.3 GSK Orally Administered Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 GSK Orally Administered Vaccine Product Portfolio
  24. 7.4.5 GSK Recent Developments
  25. 7.5 Tiantan Biological
  26. 7.5.1 Tiantan Biological Company Information
  27. 7.5.2 Tiantan Biological Business Overview
  28. 7.5.3 Tiantan Biological Orally Administered Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Tiantan Biological Orally Administered Vaccine Product Portfolio
  30. 7.5.5 Tiantan Biological Recent Developments
  31. 7.6 Valneva
  32. 7.6.1 Valneva Company Information
  33. 7.6.2 Valneva Business Overview
  34. 7.6.3 Valneva Orally Administered Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Valneva Orally Administered Vaccine Product Portfolio
  36. 7.6.5 Valneva Recent Developments
  37. 7.7 Vabiotech
  38. 7.7.1 Vabiotech Company Information
  39. 7.7.2 Vabiotech Business Overview
  40. 7.7.3 Vabiotech Orally Administered Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Vabiotech Orally Administered Vaccine Product Portfolio
  42. 7.7.5 Vabiotech Recent Developments
  43. 7.8 Shanghai United Cell
  44. 7.8.1 Shanghai United Cell Company Information
  45. 7.8.2 Shanghai United Cell Business Overview
  46. 7.8.3 Shanghai United Cell Orally Administered Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Shanghai United Cell Orally Administered Vaccine Product Portfolio
  48. 7.8.5 Shanghai United Cell Recent Developments
  49. 7.9 Serum Institute
  50. 7.9.1 Serum Institute Company Information
  51. 7.9.2 Serum Institute Business Overview
  52. 7.9.3 Serum Institute Orally Administered Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Serum Institute Orally Administered Vaccine Product Portfolio
  54. 7.9.5 Serum Institute Recent Developments
  55. 7.10 PaxVax
  56. 7.10.1 PaxVax Company Information
  57. 7.10.2 PaxVax Business Overview
  58. 7.10.3 PaxVax Orally Administered Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 PaxVax Orally Administered Vaccine Product Portfolio
  60. 7.10.5 PaxVax Recent Developments
  61. 7.11 Panacea Biotec Ltd
  62. 7.11.1 Panacea Biotec Ltd Company Information
  63. 7.11.2 Panacea Biotec Ltd Business Overview
  64. 7.11.3 Panacea Biotec Ltd Orally Administered Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Panacea Biotec Ltd Orally Administered Vaccine Product Portfolio
  66. 7.11.5 Panacea Biotec Ltd Recent Developments
  67. 7.12 Halfkin Bio-Pharmaceuticals
  68. 7.12.1 Halfkin Bio-Pharmaceuticals Company Information
  69. 7.12.2 Halfkin Bio-Pharmaceuticals Business Overview
  70. 7.12.3 Halfkin Bio-Pharmaceuticals Orally Administered Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Halfkin Bio-Pharmaceuticals Orally Administered Vaccine Product Portfolio
  72. 7.12.5 Halfkin Bio-Pharmaceuticals Recent Developments
  73. 7.13 EuBiologics
  74. 7.13.1 EuBiologics Company Information
  75. 7.13.2 EuBiologics Business Overview
  76. 7.13.3 EuBiologics Orally Administered Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 EuBiologics Orally Administered Vaccine Product Portfolio
  78. 7.13.5 EuBiologics Recent Developments
  79. 7.14 Bio-Med
  80. 7.14.1 Bio-Med Company Information
  81. 7.14.2 Bio-Med Business Overview
  82. 7.14.3 Bio-Med Orally Administered Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 Bio-Med Orally Administered Vaccine Product Portfolio
  84. 7.14.5 Bio-Med Recent Developments
  85. 7.15 Bibcol
  86. 7.15.1 Bibcol Company Information
  87. 7.15.2 Bibcol Business Overview
  88. 7.15.3 Bibcol Orally Administered Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  89. 7.15.4 Bibcol Orally Administered Vaccine Product Portfolio
  90. 7.15.5 Bibcol Recent Developments
8 North America
  1. 8.1 North America Orally Administered Vaccine Market Size by Type
  2. 8.1.1 North America Orally Administered Vaccine Revenue by Type (2021-2032)
  3. 8.1.2 North America Orally Administered Vaccine Sales by Type (2021-2032)
  4. 8.1.3 North America Orally Administered Vaccine Price by Type (2021-2032)
  5. 8.2 North America Orally Administered Vaccine Market Size by Application
  6. 8.2.1 North America Orally Administered Vaccine Revenue by Application (2021-2032)
  7. 8.2.2 North America Orally Administered Vaccine Sales by Application (2021-2032)
  8. 8.2.3 North America Orally Administered Vaccine Price by Application (2021-2032)
  9. 8.3 North America Orally Administered Vaccine Market Size by Country
  10. 8.3.1 North America Orally Administered Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Orally Administered Vaccine Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Orally Administered Vaccine Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Orally Administered Vaccine Market Size by Type
  2. 9.1.1 Europe Orally Administered Vaccine Revenue by Type (2021-2032)
  3. 9.1.2 Europe Orally Administered Vaccine Sales by Type (2021-2032)
  4. 9.1.3 Europe Orally Administered Vaccine Price by Type (2021-2032)
  5. 9.2 Europe Orally Administered Vaccine Market Size by Application
  6. 9.2.1 Europe Orally Administered Vaccine Revenue by Application (2021-2032)
  7. 9.2.2 Europe Orally Administered Vaccine Sales by Application (2021-2032)
  8. 9.2.3 Europe Orally Administered Vaccine Price by Application (2021-2032)
  9. 9.3 Europe Orally Administered Vaccine Market Size by Country
  10. 9.3.1 Europe Orally Administered Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Orally Administered Vaccine Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Orally Administered Vaccine Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Orally Administered Vaccine Market Size by Type
  2. 10.1.1 China Orally Administered Vaccine Revenue by Type (2021-2032)
  3. 10.1.2 China Orally Administered Vaccine Sales by Type (2021-2032)
  4. 10.1.3 China Orally Administered Vaccine Price by Type (2021-2032)
  5. 10.2 China Orally Administered Vaccine Market Size by Application
  6. 10.2.1 China Orally Administered Vaccine Revenue by Application (2021-2032)
  7. 10.2.2 China Orally Administered Vaccine Sales by Application (2021-2032)
  8. 10.2.3 China Orally Administered Vaccine Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Orally Administered Vaccine Market Size by Type
  2. 11.1.1 Asia Orally Administered Vaccine Revenue by Type (2021-2032)
  3. 11.1.2 Asia Orally Administered Vaccine Sales by Type (2021-2032)
  4. 11.1.3 Asia Orally Administered Vaccine Price by Type (2021-2032)
  5. 11.2 Asia Orally Administered Vaccine Market Size by Application
  6. 11.2.1 Asia Orally Administered Vaccine Revenue by Application (2021-2032)
  7. 11.2.2 Asia Orally Administered Vaccine Sales by Application (2021-2032)
  8. 11.2.3 Asia Orally Administered Vaccine Price by Application (2021-2032)
  9. 11.3 Asia Orally Administered Vaccine Market Size by Country
  10. 11.3.1 Asia Orally Administered Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Orally Administered Vaccine Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Orally Administered Vaccine Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Orally Administered Vaccine Market Size by Type
  2. 12.1.1 SAMEA Orally Administered Vaccine Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Orally Administered Vaccine Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Orally Administered Vaccine Price by Type (2021-2032)
  5. 12.2 SAMEA Orally Administered Vaccine Market Size by Application
  6. 12.2.1 SAMEA Orally Administered Vaccine Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Orally Administered Vaccine Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Orally Administered Vaccine Price by Application (2021-2032)
  9. 12.3 SAMEA Orally Administered Vaccine Market Size by Country
  10. 12.3.1 SAMEA Orally Administered Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Orally Administered Vaccine Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Orally Administered Vaccine Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Orally Administered Vaccine Value Chain Analysis
  2. 13.1.1 Orally Administered Vaccine Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Orally Administered Vaccine Production Mode & Process
  6. 13.2 Orally Administered Vaccine Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Orally Administered Vaccine Distributors
  9. 13.2.3 Orally Administered Vaccine Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst